Disturbances of cutaneous microcirculation in patients with diabetic legs: additional parameters for a new therapeutic concept?
To study disturbed microcirculation involved in the pathogenesis of diabetic neuropathic plantar ulcers (DNPU), we recorded dynamic changes in laser-Doppler flux (LDF) and cutaneous oxygen tension (pcuO2) caused by short-time arterial occlusion and local heating at three different sites (forefoot, ulcer edge, lower leg) in patients (n = 14) with DNPU and healthy controls (n = 18). Significantly reduced dynamic pcuO2 parameters coincided with a significant increase of flux in the patient group. This post-stimulatory "hypoxic hyperemia" indicates a shifting of blood flux, reducing circulation of the nutritive capillaries comparable to an internal "steal effect". This may predispose to the development of DNPU when additional stresses influence the initial borderline balance, characterized by similar pcuO2 and increased flux values compared to controls. Abolishment of normal vasoconstriction in the shunt vessels by diabetic polyneuropathy is the assumed cause of increased arteriovenous perfusion and therefore raised flux values. Non-invasive testing of microcirculatory functions demonstrates characteristic disturbances in DNPU patients and could be used as additional parameters for new therapeutic concepts as the intravenous retrograde perfusion (RVP). After RVP therapy, applied to a subgroup (n = 7) of the patients, some dynamic microcirculatory parameters improved, allowing a preliminary quantitative evaluation of a therapeutic regimen.
Department of Dermatology, University of Erlangen-Nuernberg, Germany.
S
S
Bühler-Singer
D
D
Hiller
H P
HP
Albrecht
C
C
Seidel
O P
OP
Hornstein
D000328:Adult; D000368:Aged; D010478:Chemotherapy, Cancer, Regional Perfusion; D003907:Dexamethasone / Q000008:administration & dosage; D003925:Diabetic Angiopathies / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D017719:Diabetic Foot / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D004359:Drug Therapy, Combination; D005839:Gentamicins / Q000008:administration & dosage; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D017078:Laser-Doppler Flowmetry; D007866:Leg / Q000098:blood supply*; D008012:Lidocaine / Q000008:administration & dosage; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D010100:Oxygen / Q000032:analysis; D011759:Pyrrolidines / Q000008:administration & dosage; D012867:Skin / Q000378:metabolism; D014463:Ultrasonography; D014665:Vasodilator Agents / Q000008:administration & dosage
D005839:Gentamicins; D011759:Pyrrolidines; D014665:Vasodilator Agents; D003907:Dexamethasone; D006493:Heparin; D008012:Lidocaine; D010100:Oxygen; C010651:buflomedil